Neurovance has been spun out of Euthymics Bioscience, Inc. to advance EB-1020, a norepinephrine and dopamine-preferring reuptake inhibitor for ADHD. In addition to EB-1020, Neurovance also holds a substantial portfolio of research stage reuptake inhibitors.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/18/12 | $7,000,000 | Series A-1 |
Novartis Venture Funds | undisclosed |
| 04/03/14 | $6,300,000 | Series A-1 Extension |
GBS Venture Partners H&Q Healthcare Investors H&Q Life Sciences Investors Novartis Venture Funds State of Wisconsin Investment Board Venture Investors | undisclosed |
